Researchers from Exscientia and the University of Oxford have developed an advanced predictive model called ABodyBuilder3 for antibody structures. This new tool is key for creating monoclonal antibodies, which are integral in immune responses and therapeutic applications. The novel model improves upon the previous ABodyBuilder2 by enhancing the accuracy of predicting Complementarity Determining Region (CDR)…
